Cite
HARVARD Citation
Vansteenkiste, J. et al. (n.d.). Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology. 17 (6), pp. 822-835. [Online].